CO6300953A2 - Antagonistas del receptor mineralcorticoide y metodos de uso - Google Patents

Antagonistas del receptor mineralcorticoide y metodos de uso

Info

Publication number
CO6300953A2
CO6300953A2 CO10072532A CO10072532A CO6300953A2 CO 6300953 A2 CO6300953 A2 CO 6300953A2 CO 10072532 A CO10072532 A CO 10072532A CO 10072532 A CO10072532 A CO 10072532A CO 6300953 A2 CO6300953 A2 CO 6300953A2
Authority
CO
Colombia
Prior art keywords
methods
compound
formula
mineralcorticoid
pharmaceutically acceptable
Prior art date
Application number
CO10072532A
Other languages
English (en)
Spanish (es)
Inventor
Konstantinos Gavardinas
Prabhakar Kondaji Jadhav
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300953(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO6300953A2 publication Critical patent/CO6300953A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CO10072532A 2007-12-19 2010-06-16 Antagonistas del receptor mineralcorticoide y metodos de uso CO6300953A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19

Publications (1)

Publication Number Publication Date
CO6300953A2 true CO6300953A2 (es) 2011-07-21

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10072532A CO6300953A2 (es) 2007-12-19 2010-06-16 Antagonistas del receptor mineralcorticoide y metodos de uso

Country Status (33)

Country Link
US (1) US7994164B2 (https=)
EP (2) EP2235007B1 (https=)
JP (1) JP5562866B2 (https=)
KR (1) KR101254382B1 (https=)
CN (1) CN101903377B (https=)
AR (1) AR069554A1 (https=)
AU (1) AU2008343524B2 (https=)
BR (1) BRPI0820805A2 (https=)
CA (1) CA2710409C (https=)
CL (1) CL2008003600A1 (https=)
CO (1) CO6300953A2 (https=)
DK (1) DK2235007T3 (https=)
DO (1) DOP2010000185A (https=)
EA (1) EA017668B1 (https=)
EC (2) ECSP10010266A (https=)
ES (2) ES2396605T3 (https=)
GT (1) GT201000179A (https=)
HR (1) HRP20120916T1 (https=)
IL (1) IL206353A (https=)
MA (1) MA31910B1 (https=)
MX (1) MX2010006911A (https=)
MY (1) MY150474A (https=)
NZ (1) NZ586300A (https=)
PE (1) PE20091057A1 (https=)
PL (1) PL2235007T3 (https=)
PT (1) PT2235007E (https=)
RS (1) RS52594B (https=)
SI (1) SI2235007T1 (https=)
TN (1) TN2010000292A1 (https=)
TW (1) TWI431010B (https=)
UA (1) UA100131C2 (https=)
WO (1) WO2009085584A1 (https=)
ZA (1) ZA201004257B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693997C (en) 2007-08-03 2013-01-15 Pierre L. Beaulieu Viral polymerase inhibitors
CN101903351B (zh) 2007-12-19 2014-09-10 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
WO2010104721A1 (en) * 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
EA027936B1 (ru) 2013-05-02 2017-09-29 Пфайзер Инк. Производные имидазотриазина в качестве ингибиторов фосфодиэстеразы 10 (pde10)
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
EP3160948B1 (en) 2014-06-30 2018-10-24 Astrazeneca AB Benzoxazinone amides as mineralocorticoid receptor modulators
NZ730759A (en) * 2014-11-21 2018-10-26 Lilly Co Eli 1,2-benzothiazole compounds for the treatment of kidney disorders
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CR20240015A (es) * 2016-09-24 2024-04-05 Novo Nordisk As COMPOSICIÓN FARMACÉUTICA CON ANTAGONISTA DEL RECEPTOR DE MINERALOCORTICOIDES Y SU USO (Divisional Expediente 2019-203)
JP7697961B2 (ja) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
US4999363A (en) 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
CN1911930A (zh) * 2001-11-21 2007-02-14 千禧药品公司 趋化因子受体拮抗剂及其方法和用途
TW200400816A (en) * 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
US7482344B2 (en) 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
US20090054417A1 (en) * 2004-07-28 2009-02-26 Irm Llc Compounds and compositions as modulators of steroid hormone nuclear receptors
ES2547724T3 (es) 2004-11-10 2015-10-08 Incyte Corporation Compuestos de lactama y su uso como productos farmacéuticos
DK2089367T3 (da) 2006-10-31 2012-02-06 Pfizer Prod Inc Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister
EP2142194A1 (en) 2007-03-29 2010-01-13 N.V. Organon Mineralocorticoid receptor antagonists
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP2252615A1 (en) 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Also Published As

Publication number Publication date
MA31910B1 (fr) 2010-12-01
JP5562866B2 (ja) 2014-07-30
IL206353A (en) 2014-06-30
ECSP12012048A (es) 2012-08-31
EP2537845B1 (en) 2014-03-19
DK2235007T3 (da) 2012-12-17
KR101254382B1 (ko) 2013-04-15
AU2008343524B2 (en) 2012-03-08
EP2235007A1 (en) 2010-10-06
AR069554A1 (es) 2010-02-03
MX2010006911A (es) 2010-10-05
MY150474A (en) 2014-01-30
PL2235007T3 (pl) 2013-03-29
DOP2010000185A (es) 2010-09-15
SI2235007T1 (sl) 2013-01-31
CL2008003600A1 (es) 2010-02-19
JP2011507868A (ja) 2011-03-10
EA017668B1 (ru) 2013-02-28
TW200930721A (en) 2009-07-16
CA2710409C (en) 2012-11-06
KR20100082866A (ko) 2010-07-20
WO2009085584A1 (en) 2009-07-09
NZ586300A (en) 2012-06-29
HK1144284A1 (en) 2011-02-11
EP2537845A1 (en) 2012-12-26
IL206353A0 (en) 2010-12-30
ES2459318T3 (es) 2014-05-09
ECSP10010266A (es) 2010-07-30
HRP20120916T1 (hr) 2012-12-31
TWI431010B (zh) 2014-03-21
EP2235007B1 (en) 2012-10-31
ZA201004257B (en) 2011-11-30
AU2008343524A1 (en) 2009-07-09
CA2710409A1 (en) 2009-07-09
US7994164B2 (en) 2011-08-09
RS52594B (sr) 2013-04-30
CN101903377A (zh) 2010-12-01
TN2010000292A1 (en) 2011-11-11
PE20091057A1 (es) 2009-07-20
BRPI0820805A2 (pt) 2015-06-16
EA201070762A1 (ru) 2010-12-30
GT201000179A (es) 2012-04-16
CN101903377B (zh) 2014-07-09
PT2235007E (pt) 2013-01-22
UA100131C2 (uk) 2012-11-26
ES2396605T3 (es) 2013-02-22
US20090163472A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
CO6300953A2 (es) Antagonistas del receptor mineralcorticoide y metodos de uso
CL2011002989A1 (es) Compuestos heterociclicos inhibidores de la endopeptidasa neutra (nep); composicion farmaceutica; combinacion farmaceutica; uso del compuesto patra tratar un trastorno o enfermedad tal como hipertencion, insuficiencia cardiaca, insuficiencia renal, epilepsia, sindrome metabolico, entre otros.
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
BRPI0714315B8 (pt) arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende
MX2009006795A (es) Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma.
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
UY32062A (es) Inhibidores de beta-secretasa
WO2009054423A1 (ja) オキサジアゾリジンジオン化合物
CL2011001848A1 (es) Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras.
MX336881B (es) Compuestos heterociclicos triciclicos.
CY1110922T1 (el) Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
CR20210085A (es) Compuestos de 2,6-diaminopiridina
CO2021016870A2 (es) Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2009018226A3 (en) Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e)
EA201171125A1 (ru) Антагонист минералокортикоидного рецептора и способы его применения
MX2016000188A (es) Formas de dosificacion farmaceutica estabilizadas que comprenden atrasentan.
DK1951659T3 (da) Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf
MX2012015112A (es) Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar.
WO2012163088A3 (zh) 肾病和心脏病的治疗药物及其用途
CR11471A (es) Antagonista del receptor mineralcorticoide y metodos de uso
DK1919896T3 (da) Aminoarylsulfonamidderivater, som funktionelle 5-HT6-ligander

Legal Events

Date Code Title Description
FC Application refused